BiotechTube

ZN-c3 + Encorafenib + Cetuximab

Phase 1Terminated
2 views this week 0 watching💤 Quiet
Interest: 11/100
11
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastatic Colorectal Cancer

Conditions

Metastatic Colorectal Cancer

Trial Timeline

Feb 27, 2023 → Jul 9, 2025

NCT ID
NCT05743036

About ZN-c3 + Encorafenib + Cetuximab

ZN-c3 + Encorafenib + Cetuximab is a phase 1 stage product being developed by Zentalis Pharmaceuticals for Metastatic Colorectal Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT05743036. Target conditions include Metastatic Colorectal Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Metastatic Colorectal Cancer were approved

Approved (20) Terminated (8) Active (0)
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enfortumab VedotinAstellas PharmaApproved
✅EligardAstellas PharmaApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Eli LillyApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05743036Phase 1Terminated

Competing Products

20 competing products in Metastatic Colorectal Cancer

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
17
AbemaciclibEli LillyPre-clinical
26
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
44
SYNB1891 + AtezolizumabSynlogicPhase 1
11
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 3
40
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 1/2
32
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
21
Induction therapyChugai PharmaceuticalPhase 2
42
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
40
Paclitaxel + Bevacizumab + Letrozole + Anastrozole + Exemestane + Fulvestrant + Goserelin + leuprorelinChugai PharmaceuticalPhase 2
35
bevacizumab + PaclitaxelChugai PharmaceuticalPhase 2
35
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
31
GC33Chugai PharmaceuticalPhase 1
29
Gemcitabine and UFTE chemotherapyYuhanPhase 2
35
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
44
DS9051bDaiichi SankyoPhase 1
36